Caryn M. Upton

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie et al. · The Lancet Infectious Diseases · 2021 · 117 citations · Full text

Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis, Pharmacology +8

Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial

Caryn M. Upton, Rob C. van Wijk, Laurynas Mockeliūnas et al. · EClinicalMedicine · 2022 · 82 citations · Full text

The collaborative UK ECMO trial: Follow-up to 1 year of age

Margaret Johnson, D Field, Diana Elbourne et al. · UCL Discovery (University College London) · 1998 · 67 citations

Pediatrics, Health Policy

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Müge Çevik, Lindsay C Thompson, Caryn M. Upton et al. · The Lancet Infectious Diseases · 2024 · 47 citations · Full text

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Andreas H. Diacon, Clifton E. Barry, Alex Carlton et al. · Nature Medicine · 2024 · 38 citations · Full text